-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RKGStEV9JmzkhrFVyUCADDqVRRb8FOxulO6mJII6At66aCdQVzwdL9fPYioo6ozI wInXq3odP1YyrtV4TBU7dA== 0001005477-98-003253.txt : 19981118 0001005477-98-003253.hdr.sgml : 19981118 ACCESSION NUMBER: 0001005477-98-003253 CONFORMED SUBMISSION TYPE: 8-A12G/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 19981116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: METRA BIOSYSTEMS INC CENTRAL INDEX KEY: 0000888999 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 330408436 STATE OF INCORPORATION: CA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-A12G/A SEC ACT: SEC FILE NUMBER: 000-26234 FILM NUMBER: 98751923 BUSINESS ADDRESS: STREET 1: 265 N WHISMAN RD CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 4159039100 MAIL ADDRESS: STREET 1: 265 NORTH WHISMAN RD CITY: MOUNTAIN VIEW STATE: CA ZIP: 940433911 8-A12G/A 1 AMENDMENT NO. 2 TO FORM 8-A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ----------- FORM 8-A/A2 FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12 (b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 METRA BIOSYSTEMS, INC. ---------------------- (Exact name of registrant as specified in its charter) California 33-0408436 - ---------------------------------------- ------------------- (State of incorporation or organization) (IRS Employer Identification No.) 265 North Whisman Road, Mountain View, CA 94043 - ----------------------------------------- ---------- (Address of principal executive offices) (Zip Code) Securities to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which to be so registered each class is to be registered ------------------- ------------------------------ None None Securities to be registered pursuant to Section 12(g) of the Act: Preferred Share Purchase Rights ------------------------------- (Title of Class) Item 1. Description of Securities to be Registered. On August 21, 1996, the Board of Directors of Metra Biosystems, Inc. (the "Company") declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of Common Stock, $0.001 par value (the "Common Shares"), of the Company. The dividend is payable on September 5, 1996 (the "Record Date") to shareholders of record as of the close of business on that date. Each Right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series A Participating Preferred Stock, $0.001 par value, of the Company (the "Preferred Shares"), subject to adjustment, at a price of $50.00 per share, subject to adjustment (the "Purchase Price"). The description and terms of the Rights are set forth in a Preferred Shares Rights Agreement (as amended, the "Rights Agreement") dated as of August 21, 1996, and as amended January 17, 1997 and November 3, 1998, between the Company and American Stock Transfer & Trust Company (the "Rights Agent"). The following is a general description only and is subject to the detailed terms and conditions of the Rights Agreement. A copy of the Rights Agreement, including the Certificate of Determination, the form of Rights Certificate and the Summary of Rights to be provided to shareholders of the Company, is attached as Exhibit 1 to this Registration Statement and is incorporated herein by reference. A copy of Amendment No. 1 to the Rights Agreement is attached as Exhibit 2 to this Registration Statement and is incorporated herein by reference. A copy of Amendment No. 2 to the Rights Agreement is attached as Exhibit 3 to this Registration Statement and is incorporated herein by reference. Rights Evidenced by Common Share Certificates The Rights will not be exercisable until the Distribution Date (defined below). Accordingly, Common Share certificates outstanding on the Record Date will evidence the Rights related thereto, and Common Share certificates issued after the Record Date will contain a notation incorporating the Rights Agreement by reference. Until the Distribution Date (or earlier redemption, exchange or expiration of the Rights), the surrender or transfer of any certificates for Common Shares, even without notation or a copy of the Summary of Rights being attached thereto, will also constitute the transfer of the Rights associated with the Common Shares represented by such certificate. Distribution Date The Rights will separate from the Common Shares, certificates for the Rights ("Rights Certificates") will be issued and the Rights will become exercisable upon the earlier of: (i) the close of business on the tenth day (or such later date as may be determined by a majority of the Board of Directors, excluding directors affiliated with the Acquiring Person, as defined below (the "Continuing Directors")) following a public announcement that a person or group of affiliated or associated persons has acquired, or obtained the right to acquire, beneficial ownership of 20% (or in the case of Citigroup Inc. and its affiliates only, 28%) or more of the outstanding Common Shares (an "Acquiring Person"), subject to certain exceptions set forth in the Rights Agreement, or (ii) the close of business on the tenth day (or such later date as may be determined -2- by a majority of the Continuing Directors) following the commencement of a tender offer or exchange offer, the consummation of which would result in the beneficial ownership by a person or group of 30% or more of the outstanding Common Shares. The earlier of such dates is referred to as the "Distribution Date". Issuance of Rights Certificates, Expiration of Rights As soon as practicable following the Distribution Date, separate Rights Certificates will be mailed to holders of record of the Common Shares as of the close of business on the Distribution Date and such separate Rights Certificates alone will evidence the Rights from and after the Distribution Date. Unless otherwise determined by the Board of Directors, all Common Shares issued prior to the Distribution Date will be issued with Rights. Common Shares issued after the Distribution Date may be issued with Rights if such shares are issued (i) upon the exercise, conversion or exchange of securities issued after adoption of the Rights Agreement or (ii) pursuant to the exercise of stock options or under any employee benefit plan or arrangement. Except as otherwise determined by the Board of Directors, no other Common Shares issued after the Distribution Date will be issued with Rights. In addition, no Common Shares issued after the Distribution Date will be issued with Rights if such issuance would result in (or create a significant risk) (i) of material adverse tax consequences to the Company or the person to whom such Rights Certificate would be issued or (ii) that such options or plans would not qualify for otherwise available special tax treatment. The Rights will expire on August 21, 2006 (the "Final Expiration Date"), unless the Final Expiration Date is extended or unless the Rights are earlier redeemed or exchanged by the Company or expire upon consummation of certain mergers, consolidations or sales of assets, as described below. Initial Exercise of the Rights Following the Distribution Date, and until the occurrence of one of the subsequent events described below, holders of the Rights will be entitled to receive, upon exercise and the payment of $50.00 (the "Purchase Price") per Right, one one-thousandth of a Preferred Share. Exchange Provision At any time after an Acquiring Person has become such and prior to the Acquiring Person beneficially owning 50% or more of the outstanding Common Shares, the Board of Directors of the Company may exchange the Rights (other than Rights owned by the Acquiring Person or its affiliates), in whole or in part, at an exchange ratio of one Common Share per Right (subject to adjustment). Right to Buy Common Shares at Half Price Unless the Rights are earlier redeemed or exchanged, in the event that an Acquiring Person becomes such, other than pursuant to a tender offer which is made for all of the outstanding Common Shares and approved by a majority of the Continuing Directors after determining that the offer is both adequate and otherwise in the best interests of the Company -3- and its shareholders (a "Permitted Offer"), then proper provision will be made so that each holder of a Right which has not theretofore been exercised (other than Rights beneficially owned by the Acquiring Person, which will thereafter be void) will thereafter have the right to receive, upon exercise of a Right, a number of Common Shares having a then current value equal to two times the Purchase Price. In the event that the Company does not have a sufficient number of Common Shares available, or the Board decides that such action is necessary or appropriate and not contrary to the interests of Rights holders, the Company may, among other things, instead substitute cash, assets or other securities for the Common Shares into which the Rights would have otherwise been exercisable. Right to Buy Acquiring Company Stock at Half Price Similarly, unless the Rights are earlier redeemed or exchanged, in the event that, after the Shares Acquisition Date (as defined below), (i) the Company consolidates with or merges into another entity, (ii) another entity consolidates with or merges into the Company or (iii) the Company sells or otherwise transfers 50% or more of its consolidated assets or earning power, proper provision must be made so that each holder of a Right which has not theretofore been exercised (other than Rights beneficially owned by the Acquiring Person, which will thereafter be void) will thereafter have the right to receive, upon exercise, a number of shares of common stock of the acquiring company having a then current value equal to two times the Purchase Price (unless the transaction satisfies certain conditions and is consummated with a person who acquired shares pursuant to a Permitted Offer, in which case the Rights will expire). Adjustments to Prevent Dilution The Purchase Price payable, the number of Rights and the number of Preferred Shares, Common Shares or other securities or property issuable upon exercise of the Rights are subject to adjustment from time to time to prevent dilution as set forth in the Rights Agreement. With certain exceptions, no adjustment in the Purchase Price will be required until cumulative adjustments require an adjustment of at least 1% in such Purchase Price. Rights and Preferences of the Preferred Shares Preferred Shares purchasable upon exercise of the Rights will not be redeemable. Each Preferred Share will be entitled to an aggregate dividend of 1,000 times the dividend declared per Common Share. In the event of liquidation, the holders of the Preferred Shares will be entitled to a preferential liquidation payment equal to accrued but unpaid dividends plus the greater of $1,000 per share and 1,000 times the aggregate per share amount to be distributed to the holders of Common Shares. Each Preferred Share will have 1,000 votes, voting together with the holders of Common Shares, except as required by law or the Certificate of Determination of Rights, Preferences and Privileges of Series A Participating Preferred Stock. In the event of any merger, consolidation or other transaction in which Common Shares are changed or exchanged, each Preferred Share will be entitled to receive 1,000 times the amount received per Common Share. These rights are protected by customary anti-dilution provisions. Because of the nature of the dividend, liquidation and voting rights of the Preferred Shares, the value of the one one- -4- thousandth interest in a Preferred Share purchasable upon exercise of each Right should approximate the value of one Common Share. Redemption At any time prior to the close of business on the earlier of (i) the tenth day following the date (the "Shares Acquisition Date") of public announcement that an Acquiring Person has become such or such later date as may be determined by a majority of the Continuing Directors and publicly announced by the Company or (ii) the Final Expiration Date of the Rights, the Company may redeem the Rights in whole, but not in part, at a price of $0.01 per Right ("Redemption Price"). No Shareholders' Rights Prior to Exercise Until a Right is exercised, the holder thereof, as such, will have no rights as a shareholder of the Company (other than any rights resulting from such holder's ownership of Common Shares), including, without limitation, the right to vote or to receive dividends. Amendment of Rights Agreement The provisions of the Rights Agreement may be supplemented or amended by the Board of Directors in any manner prior to the Distribution Date without the approval of Rights holders. After the Distribution Date, the provisions of the Rights Agreement may be supplemented or amended by the Board in order to (i) cure any ambiguity, defect or inconsistency, (ii) to make changes which are deemed necessary or advisable and do not adversely affect the interests of holders of Rights (excluding the interests of any Acquiring Person), or to shorten or lengthen any time period under the Rights Agreement; provided, however, that no amendment to lengthen (A) the time period governing redemption shall be made at such time as the Rights are not redeemable, or (B) any other period unless for the purpose of protecting, enhancing or clarifying the rights of, and/or benefits to, the holders of Rights. Certain Anti-takeover Effects The Rights approved by the Board are designed to protect and maximize the value of the outstanding equity interests in the Company in the event of an unsolicited attempt by an acquiror to take over the Company, in a manner or on terms not approved by the Board of Directors. Takeover attempts frequently include coercive tactics to deprive a corporation's Board of Directors and its shareholders of any real opportunity to determine the destiny of the corporation. The Rights have been declared by the Board in order to deter such tactics, including a gradual accumulation of shares in the open market of a 20% (or in the Citigroup Inc. and its affiliates only, 28%) or greater position to be followed by a merger or a partial or two-tier tender offer that does not treat all shareholders equally. These tactics unfairly pressure shareholders, squeeze them out of their investment without giving them any real choice and deprive them of the full value of their shares. -5- The Rights are not intended to prevent a takeover of the Company and will not do so. The Rights are not exercisable in the event of a Permitted Offer, as described above. The Rights may be redeemed by the Company at $0.01 Right within ten days (or such later date as may be determined by a majority of the Continuing Directors) after the accumulation of 20% (or in the case of Citigroup Inc. and its affiliates only, 28%) or more of the Company's outstanding Common Shares by a single acquiror or group, subject to certain exceptions for transactions approved by the Board of Directors. Accordingly, the Rights should not preclude any merger or business combination approved by the Board of Directors. Issuance of the Rights does not in any way weaken the financial strength of the Company or interfere with its business plans. The issuance of the Rights has no immediate dilutive effect, will not affect reported earnings per share, should not be taxable to the Company or to its shareholders and will not change the way in which the Company's shares are presently traded. The Company's Board of Directors believes that the Rights represent a sound and reasonable means of addressing the complex issues of corporate policy created by the current takeover environment. However, the Rights may have the effect of rendering more difficult or discouraging an acquisition of the Company deemed undesirable by the Board of Directors. The Rights may cause substantial dilution to a person or group that attempts to acquire the Company on terms or in a manner not approved by the Company's Board of Directors, except pursuant to an offer conditioned upon the negation, purchase or redemption of the Rights. Item 2. Exhibits. [*] 1. Preferred Shares Rights Agreement, dated as of August 21, 1996, between Metra Biosystems, Inc. and The First National Bank of Boston, including the Certificate of Determination of Rights, Preferences and Privileges of Series A Participating Preferred Stock, the form of Rights Certificate and the Summary of Rights attached thereto as Exhibits A, B and C, respectively. [**] 2. Amendment No. 1 to Preferred Shares Rights Agreement, dated as of January 17, 1997, between Metra Biosystems, Inc. and The First National Bank of Boston. 3. Amendment No. 2 to Preferred Shares Rights Agreement, dated as of November 3, 1998, between Metra Biosystems, Inc. and American Stock Transfer & Trust Company. * Previously filed with Registrant's registration statement on Form 8-A, dated August 22, 1996. ** Previously filed with Registrant's registration statement on Form 8-A/A, dated January 17, 1997. -6- SIGNATURE Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized. METRA BIOSYSTEMS, INC. Date: November 10, 1998 By /s/ GEORGE W. DUNBAR ------------------------------------ President, Chief Executive Officer & Chief Financial Officer METRA BIOSYSTEMS, INC. REGISTRATION STATEMENT ON FORM 8-A/A2 EXHIBIT INDEX Page Number Under Exhibit Sequential Numbering No. Exhibit System - ------- ------- -------------------- [*] 1. Preferred Shares Rights Agreement, dated as of August 21, 1996, between Metra Biosystems, Inc. and The First National Bank of Boston, including the Certificate of Determination of Rights, Preferences and Privileges of Series A Participating Preferred Stock, the form of Rights Certificate and the Summary of Rights attached thereto as Exhibits A, B and C, respectively. [**] 2. Amendment No. 1 to Preferred Shares Rights Agreement, dated as of January 17, 1997, between Metra Biosystems, Inc. and The First National Bank of Boston. 3. Amendment No. 2 to Preferred Shares Rights Agreement, dated as of November 3, 1998, between Metra Biosystems, Inc. and American Stock Transfer & Trust Company. - ----------------------------------- * Previously filed with Registrant's registration statement on Form 8-A, dated August 22, 1996. ** Previously filed with Registrant's registration statement on Form 8-A/A, dated January 17, 1997. EX-99.3 2 AMENDMENT 2 TO PREFERRED SHARES RIGHTS AGREEMENT METRA BIOSYSTEMS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY Rights Agent AMENDMENT NO. 2 TO PREFERRED SHARES RIGHTS AGREEMENT Dated as of November 3, 1998 AMENDMENT NO. 2 TO PREFERRED SHARES RIGHTS AGREEMENT This Amendment No. 2 to Preferred Shares Rights Agreement, dated November 3, 1998, amends that certain Preferred Shares Rights Agreement (the "Rights Agreement"), dated as of August 21, 1996, between Metra Biosystems, Inc., a California corporation (the "Company"), and American Stock Transfer & Trust Company (the "Rights Agent"), as amended. On November 3, 1998, the Company's Board of Directors authorized an amendment of the Rights Agreement to modify the definition of Acquiring Person (as defined in the Rights Agreement), to memorialize a change in the identity of the entity serving as Rights Agent under the Rights Agreement and to make such other modifications as are set forth herein. NOW, THEREFORE, in consideration of the promises and the mutual agreements herein set forth, the parties hereby agree as follows: 1. Section 1(a) of the Rights Agreement is hereby amended and restated to read in full as follows: "(a) "Acquiring Person" shall mean any Person who or which, together with all Affiliates and Associates of such Person, shall be the Beneficial Owner of 20% (or, in the case of Citigroup Inc. together with all Affiliates and Associates thereof ("Citigroup") only, 28%) or more of the Common Shares then outstanding, but shall not include the Company, any Subsidiary of the Company or any employee benefit plan of the Company or of any Subsidiary of the Company, or any entity holding Common Shares for or pursuant to the terms of any such plan. Notwithstanding the foregoing, no Person shall be deemed to be an Acquiring Person: (i) as the result of an acquisition of Common Shares by the Company which, by reducing the number of shares outstanding, increases the proportionate number of shares beneficially owned by such Person to 20% (or, in the case of Citigroup only, 28%) or more of the Common Shares of the Company then outstanding; provided, however, that if a Person shall become the Beneficial Owner of 20% (or, in the case of Citigroup only, 28%) or more of the Common Shares of the Company then outstanding by reason of share purchases by the Company and shall, after such share purchases by the Company, become the Beneficial Owner of any additional Common Shares of the Company, then such Person shall be deemed to be an Acquiring Person; (ii) if the Board of Directors of the Company determines in good faith that a Person who would otherwise be an "Acquiring Person" as defined pursuant to the foregoing provisions of this paragraph (a) has become such inadvertently, and such Person divests as promptly as practicable of a sufficient number of Common Shares so that such Person would no longer be an "Acquiring Person," as defined pursuant to the foregoing provisions of this paragraph (a); or (iii) with respect to any proposed acquisition by a Person of Common Shares (a "Proposed Transaction") which would otherwise constitute a Triggering Event under Section 1(a)(i), such Person satisfies all of the following conditions: (A) Such Person provides the Board of Directors of the Company (or a duly appointed committee of the Board) with ten (10) Trading Days advance written notice and a written description of the material terms of such Proposed Transaction; (B) A majority of the Directors then in office (or of a duly appointed committee of the Board) determines in good faith that the Proposed Transaction is in the best interest of the Company and its shareholders (taking into account all factors that such Directors deem relevant) (a "Favorable Determination"); provided that, such Favorable Determination is revocable at any time prior to the consummation of the Proposed Transaction if a majority of the Directors then in office (or of a duly appointed committee of the Board) determines in good faith that such revocation is in the best interest of the Company and its shareholders (taking into account all factors that such Directors deem relevant); (C) The Proposed Transaction is consummated within five (5) Trading Days of notice of a Favorable Determination; provided that, if such Person fails to satisfy the requirements of this subsection (a)(iii)(C), the satisfaction of any other subsections of this subparagraph (a)(iii) shall immediately expire and the Proposed Transaction shall again be subject to all the terms and conditions set forth herein; and (D) The Proposed Transaction is consummated on the terms presented in writing to the Board of Directors pursuant to subsection (a)(iii)(B); provided that, if such Person fails to satisfy the requirements of this subsection (a)(iii)(D), the satisfaction of any other subsections of this subparagraph (a)(iii) shall immediately expire and the Proposed Transaction, including all modifications, amendments and any and all other changes to the Proposed Transaction that gave rise to the failure to satisfy this subsection (a)(iii)(D), shall be subject to all the terms and conditions set forth herein; provided that, if at any time after a Favorable Determination, such Person proposes to become or becomes the Beneficial Owner of any additional Common Shares of the Company or any of its Subsidiaries without satisfying all the requirements of this subparagraph (a)(iii) with respect to such additional Common Shares, regardless of whether the acquisition of additional Common Shares, taken alone, would result in such Person becoming an Acquiring Person, then such Person shall be deemed to be an "Acquiring Person." " 2. Section 1(g) is hereby deleted in its entirety, and all references in the Rights Agreement to "Continuing Director" or "Continuing Directors" are hereby replaced with references to "Director" or "Directors," respectively. 3. Section 1(u) of the Rights Agreement is hereby amended and restated to read in full as follows: "(u) "Shares Acquisition Date" shall mean the first date of public announcement (which, for purposes of this definition, shall include, without limitation, a report filed pursuant to Section 13(d) under the Exchange Act) by the Company or an Acquiring Person that an Acquiring Person has become such; provided that, if such person is determined not to have become an Acquiring Person pursuant to Sections l(a)(ii) or 1(a)(iii) hereof, then no Shares Acquisition Date shall be deemed to have occurred." 4. The Rights Agreement is hereby amended to the extent necessary to provide that American Stock Transfer & Trust Company is the Rights Agent for all purposes thereunder, and any reference in the Rights Agreement to "Rights Agent" shall be deemed to be a reference to such entity. 5. Section 21 of the Rights Agreement is hereby amended and restated to read in full as follows: -2- "Section 21. Change of Rights Agent. The Rights Agent or any successor Rights Agent may resign and be discharged from its duties under this Agreement upon thirty (30) days' notice in writing mailed to the Company and to each transfer agent of the Preferred Shares and the Common Shares by registered or certified mail, and to the holders of the Rights Certificates by first-class mail. The Company may remove the Rights Agent or any successor Rights Agent upon thirty (30) days' notice in writing, mailed to the Rights Agent or successor Rights Agent, as the case may be, and to each transfer agent of the Preferred Shares and the Common Shares by registered or certified mail, and to the holders of the Rights Certificates by first-class mail. If the Rights Agent shall resign or be removed or shall otherwise become incapable of acting, the Company shall appoint a successor to the Rights Agent. If the Company shall fail to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by the resigning or incapacitated Rights Agent or by the holder of a Rights Certificate (who shall, with such notice, submit his or her Rights Certificate for inspection by the Company), then the registered holder of any Rights Certificate may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. Any successor Rights Agent, whether appointed by the Company or by such a court, shall be a corporation organized and doing business under the laws of the United States or of any state of the United States, in good standing, which is authorized under such laws to exercise corporate trust or shareholder services powers and is subject to supervision or examination by federal or state authority and which has at the time of its appointment as Rights Agent a combined capital and surplus of at least $10 million. After appointment, the successor Rights Agent shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named as Rights Agent without further act or deed; but the predecessor Rights Agent shall deliver and transfer to the successor Rights Agent any property at the time held by it hereunder, and execute and deliver any further assurance, conveyance, act or deed necessary for the purpose. Not later than the effective date of any such appointment, the Company shall file notice thereof in writing with the predecessor Rights Agent and each transfer agent of the Preferred Shares and the Common Shares, and mail a notice thereof in writing to the registered holders of the Rights Certificates. Failure to give any notice provided for in this Section 21, however, or any defect therein, shall not affect the legality or validity of the resignation or removal of the Rights Agent or the appointment of the successor Rights Agent, as the case may be." 6. Section 26 of the Rights Agreement is hereby amended and restated to read in full as follows: "Section 26. Notices. Notices or demands authorized by this Agreement to be given or made by the Rights Agent or the holder of any Rights Certificate to or on the Company shall be sufficiently given or made if sent by first-class mail, postage prepaid, addressed (until another address is filed in writing with the Rights Agent) as follows: Metra Biosystems, Inc. 265 North Whisman Road Mountain View, CA 94043 Attention: President Subject to the provisions of Section 21 hereof, any notice or demand authorized by this Agreement to be given or made by the Company or by the holder of any Rights Certificate to or on the Rights Agent shall be sufficiently given or made if sent by first-class mail, postage prepaid, addressed (until another address is filed in writing with the Company) as follows: American Stock Transfer & Trust Company 3rd Floor 6201 15th Avenue Brooklyn, NY 11219 -3- Attention: Karen Lazar Notices or demands authorized by this Agreement to be given or made by the Company or the Rights Agent to the holder of any Rights Certificate shall be sufficiently given or made if sent by first-class mail, postage prepaid, addressed to such holder at the address of such holder as shown on the registry books of the Company. Notice or demands authorized by this Agreement to be given or made by any Person seeking to comply with or subject to the requirements of Section 1(a)(iii) hereof, to or on the Company shall be sufficiently given or made upon receipt by the Company at the Company's address first listed above in this Section 26 (until another address is filed in writing with the Rights Agent)." 7. All references in the Rights Agreement to the Rights Agreement shall be deemed to refer to the Rights Agreement, as amended by Amendment No. 1 to Preferred Shares Rights Agreement and this Amendment No. 2 to Preferred Shares Rights Agreement. 8. This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. -4- IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 2 to Preferred Shares Rights Agreement to be duly executed as of the day and year first above written. METRA BIOSYSTEMS, INC. By: /s/ George W. Dunbar, Jr. ----------------------------------------- Name: George W. Dunbar, Jr. --------------------------------------- Title: President & CEO -------------------------------------- AMERICAN STOCK TRANSFER & TRUST COMPANY By: /s/ Herbert J. Lemmer ----------------------------------------- Name: Herbert J. Lemmer --------------------------------------- Title: Vice President -------------------------------------- -5- -----END PRIVACY-ENHANCED MESSAGE-----